Cenerimod was potent and efficacious in reducing markers in SLE subjects. Furthermore, cenerimod significantly ameliorated systemic and organ-specific autoimmunity in a mouse model of SLE. These results warranted the further investigation of the clinical efficacy and safety of cenerimod in patients with SLE and concomitant APS. The clinical and laboratory manifestations for the entire period of the disease are given below (table 1). Now the main manifestation of the disease in the ongoing phase 2b clinical trial (NCT03742037).

Acknowledgments This research was funded by Idorsia Pharmaceuticals Ltd.

**Antiphospholipid Syndrome in Qatar: Epidemiological, Clinical, and Immunological Characteristics**

Nabeel Abdulla, Omar Alsaeed, Fiaz Alam, Rawan Saleh, Abdulrazzakh Poli, Abdelrahim Siam, Eman Elsayed, Omar Alsaed, Fiaz Alam, Rawan Saleh, Abdulrazzakh Poli, Abdelrahim Siam

**Methods**

All patients with primary and secondary APS attending rheumatology clinics from January 2017 to May 2019 at Hamad General Hospital were identified and medical records were retrospectively reviewed.

**Results**

131 patients with APS who fulfilled revised Sapporo APS classification criteria were included- 116 women (88.5%) and 15 men (11.5%). 79 patients (60.3%) had primary and 52 patients (39.7%) had secondary APS. 41 patients (31.3%) had thrombotic event only, 64 patients (48.9%) had pregnancy morbidity only, and 26 patients (19.8%) had both thrombosis as well as pregnancy morbidity. 7 patients (5.4%) had arterial thrombosis only, 48 patients (36.6%) had venous thrombosis only and 12 patients (9.1%) had both arterial and venous thrombosis. 103 (78.6%) patients had pregnancy morbidity out of the 116 female patients. Early fetal loss was the commonest pregnancy morbidity seen in 73 patients (70.9%), followed by late fetal loss in 57 patients (53.5%).

48 patients (36.6%) had aCL IgG positive and 15 patients (11.5%) had aCL IgM positive, either one was positive in 54 patients (41.2%). 42 patients (32.1%) had B2GP IgG positive and 19 patients (15.4%) had B2GP IgM positive, either one was positive in 53 patients (40.7%). LA was positive in 121 patients (92.4%). There were 71 patients (54.2%) with single positive aPL test, 21 patients (16%) with double positive and 37 patients (28.2%) with triple positive aPL test results. LA was the most common single positive aPL test, seen in 63 patients (50.3%).

**Conclusion**

The clinical manifestation and immunological characteristics of patients with APS in Qatar are diverse. Our cohort has much higher prevalence of LA positivity compared to other cohorts around the world. We also have a higher incidence of pregnancy morbidity.

**Acknowledgements**

Study funded by Medical research center at Hamad Medical Corporation.

**Poster presentations**

**P1 Antiphospholipid Syndrome in Qatar: Epidemiological, Clinical, and Immunological Characteristics**

Nabeel Abdulla, Omar Alsaeed, Fiaz Alam, Rawan Saleh, Abdulrazzakh Poli, Abdelrahim Siam, Eman Elsayed, Omar Alsaed, Fiaz Alam, Rawan Saleh, Abdulrazzakh Poli, Abdelrahim Siam

**Purpose**

The aim of this study is to analyze epidemiological, clinical, and immunologic characteristics of primary and secondary antiphospholipid syndrome (APS) cases in Qatar.
Clinical finding are: active lupus nephritis of a kidney, relapse of venous thrombosis as a result of APS, thrombotic microangiopathy, cognitive impairment and somatogenic asthenodepressive syndrome.

Conclusions This clinical case demonstrates a patient with SLE presented in clinical features thrombosis, lupus glomerulonephritis class IV, AI 8, CI 2, high immunological disorders and concomitant APS. The difficulty in treating the patient is the consistently high immunological activity of the disease, the resistance of the therapy cytostatic and glucocorticoids, the inefficiency and intolerance of a number of oral anticoagulants: dabigatran etexilate and rivaroxaban — relapses of thrombosis, warfarin — the inability to reach the target levels of the international normalized ratio (INR) due to recurrent nosebleeds.

P3 IS THERE A RELATIONSHIP BETWEEN LUPUS ANTICOAGULANT AUTOANTIBODY AND FATIGUE IN JSLE?

1Sara Ganhão, 2Beatriz Silva, 1Mariana Rodrigues, 1Francisca Aguiar, 2,3Margarida Figueiredo-Braga, 1Iva Brito. 1Young Adult and Pediatric Rheumatology Unit, Centro Hospitalar e Universitário do Hospital de São João, Porto; 2Faculty of Medicine, University of Porto, Porto; 3Dept. of Clinical Neurosciences and Mental Health, Porto, Portugal

Background Fatigue is a common symptom in systemic lupus erythematosus (SLE) and is associated with poorer quality of life and higher depression scores. Lupus anticoagulant (AcL) refers to a subset of autoantibodies to phospholipids interfering with clotting tests, which major clinical association is thrombosis. Physical activity reduces thrombotic risk in general and is a potential therapeutic strategy for managing fatigue in SLE patients. Purpose: To compare fatigue outcomes according to AcL status in juvenile-onset SLE (jSLE).

Methods A cross-sectional sample of jSLE patients, currently aged ≥16 years, completed SF-36, HADS and FSS questionnaires between October 2018- May 2019. The study was approved by the local Ethics Committee. All patients fulfilled both 2012 and 2019 EULAR/ACR classification criteria for SLE. Juvenile-onset was defined as age at diagnosis <18 years. Demographics and clinical characteristics were collected. Statistical analysis was performed with SPSS®.

Results jSLE patients (n=30) were studied (90% female) with median age of 21 years, range 16–35, with mean (SD) age of diagnosis of 15.8 ± 2.1. Mean values (SD) of psychological assessment were: FSS 4.27 ± 1.36; Physical health SF-36 of 66.8(9.9) and Mental health SF-36 of 68.9 (17.5). 56.7% jSLE showed clinically relevant fatigue, 63.3% anxiety and 13.3% depression. Four patients (13.3%) had positive AcL autoantibody. Those had lower Fatigue Severity Scale (FSS) average scores: 3.0 (0.16) vs 4.5 (0.28), comparing to those who were negative for AcL (p=0.036). Likewise, positive AcL jSLE patients had better results in SF-36 Physical Health questionnaires (p=0.034).

Conclusions The relationship between AcL status and fatigue was not previously known. We hypothesize that the present finding may be related to physical activity, a major indication...